173 related articles for article (PubMed ID: 35187628)
21. Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in China.
Ramos M; Men P; Wang X; Ustyugova A; Lamotte M
Cost Eff Resour Alloc; 2021 Aug; 19(1):46. PubMed ID: 34348729
[TBL] [Abstract][Full Text] [Related]
22. The long-term cost-effectiveness of oral semaglutide in the Netherlands based on the PIONEER 2, 3 and 4 randomized controlled trials.
Malkin SJP; Hunt B; Huisman EL; Grand TS; Chubb B
Diabetes Res Clin Pract; 2021 May; 175():108759. PubMed ID: 33744377
[TBL] [Abstract][Full Text] [Related]
23. Cost-utility analysis of second-line anti-diabetic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Chien CL; Chen YC; Malone DC; Peng YL; Ko Y
Curr Med Res Opin; 2020 Oct; 36(10):1619-1626. PubMed ID: 32851879
[TBL] [Abstract][Full Text] [Related]
24. Cost-Utility Analysis of Once-Weekly Semaglutide, Dulaglutide, and Exenatide for Type 2 Diabetes Patients Receiving Metformin-Based Background Therapy in China.
Hu S; Wang S; Qi C; Gu S; Shi C; Mao L; Fan G
Front Pharmacol; 2022; 13():831364. PubMed ID: 35250578
[No Abstract] [Full Text] [Related]
25. Budget Impact of Oral Semaglutide Intensification versus Sitagliptin among US Patients with Type 2 Diabetes Mellitus Uncontrolled with Metformin.
Wehler E; Lautsch D; Kowal S; Davies G; Briggs A; Li Q; Rajpathak S; Alsumali A
Pharmacoeconomics; 2021 Mar; 39(3):317-330. PubMed ID: 33150566
[TBL] [Abstract][Full Text] [Related]
26. Cost-Effectiveness of the FreeStyle Libre
Jendle J; Eeg-Olofsson K; Svensson AM; Franzen S; Lamotte M; Levrat-Guillen F
Diabetes Ther; 2021 Dec; 12(12):3137-3152. PubMed ID: 34694584
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness of Once-Weekly Semaglutide 1 mg versus Canagliflozin 300 mg in Patients with Type 2 Diabetes Mellitus in a Canadian Setting.
Stafford S; Bech PG; Fridhammar A; Miresashvili N; Nilsson A; Willis M; Liu A
Appl Health Econ Health Policy; 2022 Jul; 20(4):543-555. PubMed ID: 35344191
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of second-line empagliflozin versus liraglutide for type 2 diabetes in the United States.
Reifsnider OS; Pimple P; Brand S; Bergrath Washington E; Shetty S; Desai NR
Diabetes Obes Metab; 2022 Apr; 24(4):652-661. PubMed ID: 34910356
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of once-weekly semaglutide versus dulaglutide and lixisenatide in patients with type 2 diabetes with inadequate glycemic control in Sweden.
Ericsson Å; Fridhammar A
J Med Econ; 2019 Oct; 22(10):997-1005. PubMed ID: 31044636
[No Abstract] [Full Text] [Related]
30. Cost-Effectiveness of Empagliflozin and Metformin Combination Versus Standard Care as First-Line Therapy in Patients With Type 2 Diabetes Mellitus.
Abushanab D; Liew D; Marquina C; Al-Badriyeh D; Ademi Z
Endocr Pract; 2022 Jan; 28(1):16-24. PubMed ID: 34389513
[TBL] [Abstract][Full Text] [Related]
31. The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia.
Malkin SJP; Russel-Szymczyk M; Psota M; Hlavinkova L; Hunt B
Adv Ther; 2019 Aug; 36(8):2034-2051. PubMed ID: 31168765
[TBL] [Abstract][Full Text] [Related]
32. Exploring the Appropriate Price of Semaglutide for Type 2 Diabetes Patients Based on Cost-Utility Analysis in China.
Hu S; Su X; Deng X; Wang Y
Front Pharmacol; 2021; 12():701446. PubMed ID: 34177604
[No Abstract] [Full Text] [Related]
33. Cost-effectiveness analysis of empagliflozin versus sitagliptin as second-line therapy for treatment in patients with type 2 diabetes in the United States.
Reifsnider O; Kansal A; Pimple P; Aponte-Ribero V; Brand S; Shetty S
Diabetes Obes Metab; 2021 Mar; 23(3):791-799. PubMed ID: 33236481
[TBL] [Abstract][Full Text] [Related]
34. Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States.
Valentine WJ; Hoog M; Mody R; Belger M; Pollock R
Diabetes Obes Metab; 2023 May; 25(5):1292-1300. PubMed ID: 36655340
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of empagliflozin versus weekly semaglutide as add-on therapy for Type 2 diabetes.
Zupa MF; Codario RA; Smith KJ
J Comp Eff Res; 2021 Oct; 10(15):1133-1141. PubMed ID: 34490786
[No Abstract] [Full Text] [Related]
36. Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada.
Johansen P; Håkan-Bloch J; Liu AR; Bech PG; Persson S; Leiter LA
Pharmacoecon Open; 2019 Dec; 3(4):537-550. PubMed ID: 30927241
[TBL] [Abstract][Full Text] [Related]
37. Tirzepatide 10 and 15 mg vs semaglutide 2.0 mg: A long-term cost-effectiveness analysis in patients with type 2 diabetes in the United States.
Mody R; Valentine WJ; Hoog M; Sharland H; Belger M
J Manag Care Spec Pharm; 2024 Feb; 30(2):153-162. PubMed ID: 38308628
[TBL] [Abstract][Full Text] [Related]
38. Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial.
Gullaksen S; Vernstrøm L; Sørensen SS; Ringgaard S; Laustsen C; Funck KL; Poulsen PL; Laugesen E
Diabetologia; 2023 May; 66(5):813-825. PubMed ID: 36746803
[TBL] [Abstract][Full Text] [Related]
39. Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11.
Evans M; Chubb B; Malkin SJP; Berry S; Lawson J; Hunt B
Diabetes Obes Metab; 2023 Feb; 25(2):491-500. PubMed ID: 36251282
[TBL] [Abstract][Full Text] [Related]
40. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
